Hansa Biopharma AB (publ) (LON:0RC7)

Market Cap	324.83M +104.4%
Revenue (ttm)	17.92M +29.7%
Net Income	-42.66M
EPS	-0.53
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,573
Average Volume	4,538
Open	40.02
Previous Close	36.36
Day's Range	39.20 - 40.62
52-Week Range	20.10 - 42.96
Beta	1.84
RSI	66.99
Earnings Date	Feb 11, 2026

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 133
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RC7

Financial Performance

In 2025, Hansa Biopharma AB's revenue was 222.27 million, an increase of 29.74% compared to the previous year's 171.32 million. Losses were -529.25 million, -34.44% less than in 2024.

Financial numbers in SEK